|
Media Releases |
Financial Reports |
Presen-tations |
|
08/06/2008
|
 |
|
|
| Lonza Engineering as new business unit |
• Lonza Engineering as new business unit
• Provision of engineering, facility design and maintenance services to clients in China
• Logical expansion of existing strengths in manufacturing of complex products
Basel, 6 August 2008 – Lonza announces the formation of a new business unit based in China: Lonza Engineering. This new business unit will provide engineering, facility design and maintenance services for the Chinese market, furthering Lonza’s commitment to the global pharmaceutical, biopharmaceutical and chemical industries.
There is a recognized need for effective and efficient plant, process and equipment design together with cost-efficient maintenance in the life sciences industry. Lonza Engineering will capitalize on its high level of experience in this area to meet the needs of current and new customers. The initial geographic focus will be on the market in China, and may later be expanded to global markets. The business unit will also continue to provide its services to internal customers thus strengthening the support for Lonza’s growth.
“This new business unit is a very logical expansion of our existing strengths in manufacturing of complex products. We have built chemical and biotech plants around the world, at very high levels of quality and regulatory compliance,” remarked Lukas Utiger, Head of Life Science Ingredients. “We have built strong project management and maintenance experience in China since the mid 1990’s for the construction and maintenance of cGMP and Food GMP plants which have been certified by global regulators. Our talented and highly qualified staff of 130 technical experts has a strong drive to capitalize on this new business opportunity.”
The business unit will operate as a subsidiary of Lonza Group and the management team of the new company will consist of current Lonza employees from Switzerland and China.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion. Further information can be found at www.lonza.com.
For further Information:
Lonza:
Head Corporate Communications
Janet White
Tel +41 61 316 8566
Fax +41 61 316 9566
janet.white@lonza.com
Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com
Investor Relations
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
